Janus Henderson Group
ANTX icon

Janus Henderson Group’s AN2 Therapeutics ANTX Stock Holding History

Janus Henderson Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,221,051
Closed -$2.61M – 2528
2024
Q2 		$2.61M Sell
1,221,051
-94
-0% -$224 ﹤0.01% 1130
2024
Q1 		$3.98M Sell
1,221,145
-58,830
-5% -$640K ﹤0.01% 968
2023
Q4 		$26.3M Sell
1,279,975
-108,975
-8% -$1.82M 0.02% 491
2023
Q3 		$22.1M Buy
1,388,950
+388,882
+39% +$4.4M 0.01% 515
2023
Q2 		$8.59M Buy
+1,000,068
New +$7.19M 0.01% 719

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group's ANTX Position: Q3 2024 in Review

Janus Henderson Group sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 1,221,051 shares — an estimated $2.61M sold.

Janus Henderson Group first reported a position in ANTX in Q2 2023 and held it in 5 quarters. The position peaked at $26.3M in Q4 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Janus Henderson Group reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Janus Henderson Group sold 1,221,051 AN2 Therapeutics shares in Q3 2024, an estimated $2.61M.
  • Janus Henderson Group first reported a position in AN2 Therapeutics in Q2 2023 and held it in 5 quarters.
  • Janus Henderson Group's AN2 Therapeutics position peaked at $26.3M in Q4 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Janus Henderson Group's 13F filing for Q3 2024, filed 14 Nov 2024.